In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Objective To evaluate 18F-AV-1451 tau PET binding among microtubule-associated protein tau (MAPT) mutation carriers. Methods Using a case-control study, we quantitatively and qualitatively compared tau PET scans in 10 symptomatic and 3 asymptomatic MAPT mutation carriers (n = 13, age range 42–67 years) with clinically normal (CN) participants (n = 241, age range 42–67 years) and an Alzheimer disease (AD) dementia cohort (n = 30, age range 52–67 years). Eight participants had MAPT mutations that involved exon 10 (N279K n = 5, S305N n = 2, P301L n = 1) and tend to form 4R tau pathology, and 5 had mutations outside exon 10 (V337M n = 2, R406W n = 3) and tend to form mixed 3R/4R tau pathology. Results Tau PET signal was qualitatively and quantitatively different between participants with AD, CN participants, and MAPT mutation carriers, with the greatest signal intensity in those with AD and minimal regional signal in MAPT mutation carries with mutations in exon 10. However, MAPT mutation carriers with mutations outside exon 10 had uptake levels within the AD range, which was significantly higher than both MAPT mutation carriers with mutations in exon 10 and controls. Conclusions Tau PET shows higher magnitude of binding in MAPT mutation carriers who harbor mutations that are more likely to produce AD-like tau pathology (e.g., in our series, the non–exon 10 families tend to accumulate mixed 3R/4R aggregates). Exon 10 splicing determines the balance of 3R and 4R tau isoforms, with some mutations involving exon 10 predisposing to a greater proportion of 4R aggregates and consequently a lower level of AV-1451 binding, as seen in this case series, thus supporting the notion that this tau PET ligand has specific binding properties for AD-like tau pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, even within genetically determined FTD, binding affinity varies according to different tau isoforms and strains (Jones et al., 2018) supporting varying affinity to different morphologies of tau.”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Jones et al., 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the situation in FTD is more complex due in part to pathological heterogeneity and the differential affinity for tau aggregates arising from different isoforms and with different ultrastructure (Jones et al., 2018).”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Jones et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“Patients that carry one of these specific MAPT mutations can have tau pathology similar to that seen in Alzheimer's disease (although without amyloid pathology), and so can have strongly positive results on tau PET imaging.14”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“For example, tau ligands bind to tau filaments similar in structure to Alzheimer's disease neurofibrillary tangles, which occur in people with some MAPT mutations (eg, Val337Met, Arg406Trp) but not with most other MAPT mutations or with other primary tauopathies.14,71”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [14]
In the citing paper
“18F-T807 binds P-tau in vivo in a conformation-dependent manner, with highest efficiency in MAPT mutation carriers that produce AD-like PHF pathology (Jones et al., 2018), showing increased uptake in brain regions with significant tau deposition burden and little background binding in the cortex of normal brains.”
From Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models (2019) · cites this paper as Jones et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“Many neurodegenerative diseases are characterized by the presence of tau protein pathology.(1) In these disorders, the tau protein is abnormally hyperphosphorylated before forming various types of intracellular aggregates (e.”
BackgroundRoberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 793
Self-citationMarquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Self-citationGhetti, B., Oblak, A. L., Boeve, B. F., Johnson, K. A., Dickerson, B. C., & Goedert, M. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12213 · Cited by 438 · cited 1×
“The aggregate-forming filaments come in at least 3 distinct types: homogeneous 3R, homogeneous 4R, and heterogeneous 3R/4R.(3,4) The broad spectrum of heterogeneous filaments formed with mixtures of 3R/4R tau allows diverse physical and biological properties, with more restricted properties for homogeneous 3R and 4R f…”
BackgroundSelf-citationTau exon 10 alternative splicing and tauopathies
Liu, F., & Gong, C.-X. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-8 · Cited by 323
18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
Passamonti, L., Vázquez Rodríguez, P., Hong, Y. T., Allinson, K. S. J., Williamson, D., Borchert, R. J., Sami, S., Cope, T. E., Bevan-Jones, W. R., Jones, P. S., et al. (2017) · Brain · doi:10.1093/brain/aww340 · Cited by 209
The cytoskeleton in neurodegenerative diseases
Cairns, N. J., Lee, V. M., & Trojanowski, J. Q. (2004) · The Journal of Pathology · doi:10.1002/path.1650 · Cited by 192 · cited 1×
“A striking feature of the pathology observed in MAPT mutations is that they may resemble the inclusions seen in any of these tauopathies (AD, PSP, CBD, or Pick disease).(6)”
BackgroundComparison of 18F-FDG and PiB PET in Cognitive Impairment
Lowe, V. J., Kemp, B. J., Jack, C. R., Senjem, M., Weigand, S., Shiung, M., Smith, G., Knopman, D., Boeve, B., Mullan, B., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058529 · Cited by 192 · cited 2×
“Image analysis Tau PET cortical uptake was assessed with regions of interest (ROIs) defined by an in-house–modified version of the AAL atlas (47 bilateral ROIs) as previously described.(22) Individual tau PET ROI median uptake values were normalized to cerebellar crus to calculate regionally specific standardized upta…”
MethodSelf-citation
Cited by
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationAn update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
Silva, M. C., Ferguson, F. M., Cai, Q., Donovan, K. A., Nandi, G., Patnaik, D., Zhang, T., Huang, H.-T., Lucente, D. E., Dickerson, B. C., et al. (2019) · eLife · doi:10.7554/elife.45457 · Cited by 283
“(18)F-T807 binds P-tau in vivo in a conformation-dependent manner, with highest efficiency in MAPT mutation carriers that produce AD-like PHF pathology (Jones et al., 2018), showing increased uptake in brain regions with significant tau deposition burden and little background binding in the cortex of normal brains.”
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Self-citation
Metadata
- Authors
- Jones, D. T., Knopman, D. S., Graff-Radford, J., Syrjanen, J. A., Senjem, M. L., Schwarz, C. G., Dheel, C., Wszolek, Z., Rademakers, R., Kantarci, K., Petersen, R. C., Jack, C. R., Lowe, V. J., & Boeve, B. F.
- Affiliations
- Mayo Clinic (US)
- From the Departments of Neurology (D.T.J., D.S.K., J.G.-R., C.D., R.C.P., B.F.B.), Radiology (D.T.J., C.G.S., K.K., C.R.J., V.J.L.), Health Sciences Research (J.A.S.), and Information Technology (M.L.S.), Mayo Clinic, Rochester, MN; and Departments of Neurology (Z.W.) and Neuroscience (R.R.), Mayo Clinic, Jacksonville, FL.
- ORCID
- Venue
- Neurology
- Published
- 2018-03-13
- Volume
- 90
- Issue
- 11
- Pages
- e947-e954
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC5858948
- OpenAlex
- W2786354044
- Cited by
- 71
- References
- 29
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 2 · 2023: 10 · 2022: 14 · 2021: 13 · 2020: 8 · 2019: 11 · 2018: 3
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Avid Radiopharmaceuticals
- National Institute on Aging (P50AG044170, R01AG040042, U01AG006786, R01AG011378, U01AG045390, K76AG057015, P50AG016574)
- National Institute of Neurological Disorders and Stroke (R21NS066147, P50NS072187, U54NS092089, R35NS097261)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- 18F-AV-1451, tau PET, tau isoforms, Alzheimer's disease
- MeSH terms
- Adult, Aged, Alzheimer Disease, Brain, Carbolines, Heterozygote, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Middle Aged, Mutation, tau Proteins, Radiopharmaceuticals, Protein Isoforms, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. https://app.cochat.ai/papers/10.1212/wnl.0000000000005117
- The paper
- Jones, D. T., Knopman, D. S., Graff-Radford, J., Syrjanen, J. A., Senjem, M. L., Schwarz, C. G., Dheel, C., Wszolek, Z., Rademakers, R., Kantarci, K., Petersen, R. C., Jack, C. R., Lowe, V. J., & Boeve, B. F. (2018). In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology. https://doi.org/10.1212/wnl.0000000000005117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.